Abstract: Objective To demonstrate the pharmacokinetic profile of meropenem when administered by 3-hour infusion in patients undergoing continuous veno-venous hemofiltration(CVVH).Methods The study was conducted in 10 patients,who were treated with CVVH.Each subject received meropenem in 3-hour infusion of 500 mg every 6 hours.Blood samples were collected before infusion(0 hour)and 0.25,0.5,1,1.5,2,3,4,5,6 hours (just before the infusion of the next dose)after the beginning of the fourth infusion.The concentrations of meropenem in plasma were measured by high-performance liquid chromatography method,and mean serum meropenem concentration-time curve was plotted.Results Peak plasma drug concentrations measured 3 hours post-infusion were (25.05 ±5.64)mg/L,and trough levels after 6 hours of infusion were(13.03 ±3.01)mg/L.The area under the plasma concentration-time curve(AUC)was(118.42 ± 26.78)mg· h-1 ·L-1.The elimination half-life(T1/2)was (3.74 ± 0.55)hours.The mean residence time(MRT)was(4.99 ± 0.84)hours.The volume of distribution(Vb)was (22.85 ± 9.85)L and clearance of meropenem(CL)was(4.49 ± 1.32)L/h.The percentage of time that the serum drug concentration was above the minimum inhibitory concentration(MIC)accounting for the interval time of infusion (%T>MIC)was 100%(MIC 8 mg/L)in all the 10 patients.Conclusion Based on these data,we concluded that satisfactory pharmacodynamic parameters could be attained in CVVH patients treated with meropenem by a prolonged infusion time of 3 hours with a dosage of 500 mg for every 6 hours.